IL165372A0 - Immunodenic compositions - Google Patents

Immunodenic compositions

Info

Publication number
IL165372A0
IL165372A0 IL16537203A IL16537203A IL165372A0 IL 165372 A0 IL165372 A0 IL 165372A0 IL 16537203 A IL16537203 A IL 16537203A IL 16537203 A IL16537203 A IL 16537203A IL 165372 A0 IL165372 A0 IL 165372A0
Authority
IL
Israel
Prior art keywords
immunodenic
compositions
immunodenic compositions
Prior art date
Application number
IL16537203A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0213365.0A external-priority patent/GB0213365D0/en
Priority claimed from GB0300914A external-priority patent/GB0300914D0/en
Application filed by Glaxosmithkline Biolog filed Critical Glaxosmithkline Biolog
Publication of IL165372A0 publication Critical patent/IL165372A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16537203A 2002-06-11 2003-06-06 Immunodenic compositions IL165372A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0213365.0A GB0213365D0 (en) 2002-06-11 2002-06-11 Novel compounds
GB0300914A GB0300914D0 (en) 2003-01-15 2003-01-15 Vaccines
PCT/EP2003/006096 WO2003104272A1 (fr) 2002-06-11 2003-06-06 Compositions immunogenes

Publications (1)

Publication Number Publication Date
IL165372A0 true IL165372A0 (en) 2006-01-15

Family

ID=29738082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16537203A IL165372A0 (en) 2002-06-11 2003-06-06 Immunodenic compositions

Country Status (28)

Country Link
US (1) US20060147477A1 (fr)
EP (1) EP1511768B1 (fr)
JP (1) JP2006512047A (fr)
KR (1) KR20050010040A (fr)
CN (1) CN100360558C (fr)
AR (1) AR040178A1 (fr)
AT (1) ATE359295T1 (fr)
AU (1) AU2003246411A1 (fr)
BR (1) BR0311732A (fr)
CA (1) CA2487831A1 (fr)
CO (1) CO5631450A2 (fr)
DE (1) DE60313163T2 (fr)
DK (1) DK1511768T3 (fr)
ES (1) ES2285174T3 (fr)
HK (1) HK1074846A1 (fr)
IL (1) IL165372A0 (fr)
IS (1) IS7547A (fr)
MX (1) MXPA04012443A (fr)
MY (1) MY139557A (fr)
NO (1) NO20045148L (fr)
NZ (1) NZ537125A (fr)
PE (1) PE20040554A1 (fr)
PL (1) PL374534A1 (fr)
PT (1) PT1511768E (fr)
RU (1) RU2004135541A (fr)
TW (1) TW200400970A (fr)
UY (1) UY27840A1 (fr)
WO (1) WO2003104272A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2005249212B2 (en) * 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP2008528623A (ja) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
EP1981527A4 (fr) * 2006-01-27 2011-05-04 Univ Mississippi Medical Ct Administration thermiquement ciblee de medicaments comme la doxorubicine
EP2032719A2 (fr) 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Procédé pour identifier si un patient est reactif ou non a l'immunotherapie
PL2121011T3 (pl) * 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
ES2321788B1 (es) * 2007-01-29 2010-03-11 Universidad Miguel Hernandez Dominios proteicos de afinidad a colina para mejorar la expresion, inmovilizacion y purificacion de polipetidos.
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009046739A1 (fr) 2007-10-09 2009-04-16 Curevac Gmbh Composition pour traiter le cancer de la prostate (pca)
US8466167B2 (en) 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
WO2009114202A2 (fr) * 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccin et procédé d'immunisation à l’aide d’un antigène 2 de plasmodium
WO2010036293A1 (fr) * 2008-09-24 2010-04-01 The Johns Hokins University Vaccin contre le paludisme
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
US20110229514A1 (en) * 2009-03-16 2011-09-22 Denise Doolan Vaccine and immunization method using plasmodium antigen 2
EP2411045A1 (fr) 2009-03-24 2012-02-01 Novartis AG Combinaisons de protéine liant le facteur h de méningocoque et de conjugués de saccharide de pneumocoque
CA2765112A1 (fr) 2009-06-10 2010-12-16 Novartis Ag Vaccins contenant de la benzonaphtyridine
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CA2772916C (fr) 2009-09-02 2019-01-15 Novartis Ag Compositions immunogenes comprenant des modulateurs de l'activite tlr
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
EP2528621B1 (fr) * 2010-01-27 2016-09-21 GlaxoSmithKline Biologicals S.A. Antigènes modifiés de la tuberculose
CN102905703B (zh) 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
KR102157718B1 (ko) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CN114617958A (zh) 2011-08-17 2022-06-14 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
RU2598265C2 (ru) * 2013-07-26 2016-09-20 Амир Закиевич Максютов Полиэпитопные иммуногенные полипептиды и способы их применения
WO2015164979A1 (fr) 2014-05-02 2015-11-05 Qu Biologics Inc. Immunomodulation anti-microbienne
CN108164586B (zh) * 2018-01-22 2021-03-26 西南医科大学 合成多肽及其应用
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
FR3100819B1 (fr) * 2019-09-18 2024-04-19 Centre Nat Rech Scient Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques
CN110922455B (zh) * 2019-12-28 2023-01-13 重庆艾力彼生物科技有限公司 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用
WO2022096596A1 (fr) 2020-11-04 2022-05-12 Eligo Bioscience Phages recombinants de cutibacterium acnes, leur procédé de production et leurs utilisations
CN113278078B (zh) * 2021-05-25 2023-03-21 西南医科大学 多肽序列及其应用
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用
CN117003890B (zh) * 2023-08-09 2024-06-04 成都新诺明生物科技有限公司 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
TR200100916T2 (fr) * 1998-07-14 2002-06-21 Corixa@@Corporation
WO2000029434A2 (fr) * 1998-11-19 2000-05-25 St. Jude Children's Research Hospital IDENTIFICATION ET CARACTERISATION DE NOUVELLES PROTEINES PNEUMOCOCCIQUES SE LIANT A LA CHOLINE, CbpG AND CbpD, ET UTILISATIONS DIAGNOSTIQUES ET THERAPEUTIQUES CORRESPONDANTES
WO2001034802A2 (fr) * 1999-11-12 2001-05-17 Corixa Corporation Compositions et methodes de traitement et de diagnostic du cancer de la prostate
CA2397741A1 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
CA2403909A1 (fr) * 2000-03-27 2001-10-04 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate

Also Published As

Publication number Publication date
ES2285174T3 (es) 2007-11-16
UY27840A1 (es) 2003-12-31
JP2006512047A (ja) 2006-04-13
US20060147477A1 (en) 2006-07-06
TW200400970A (en) 2004-01-16
IS7547A (is) 2004-11-23
CO5631450A2 (es) 2006-04-28
WO2003104272A1 (fr) 2003-12-18
DK1511768T3 (da) 2007-08-20
PE20040554A1 (es) 2004-09-30
MY139557A (en) 2009-10-30
PL374534A1 (en) 2005-10-31
AR040178A1 (es) 2005-03-16
CA2487831A1 (fr) 2003-12-18
ATE359295T1 (de) 2007-05-15
KR20050010040A (ko) 2005-01-26
RU2004135541A (ru) 2005-10-10
CN1675237A (zh) 2005-09-28
EP1511768A1 (fr) 2005-03-09
NZ537125A (en) 2006-08-31
CN100360558C (zh) 2008-01-09
EP1511768B1 (fr) 2007-04-11
NO20045148L (no) 2005-03-01
BR0311732A (pt) 2005-03-01
MXPA04012443A (es) 2005-04-19
DE60313163T2 (de) 2008-01-03
PT1511768E (pt) 2007-07-16
AU2003246411A1 (en) 2003-12-22
DE60313163D1 (de) 2007-05-24
HK1074846A1 (en) 2005-11-25

Similar Documents

Publication Publication Date Title
GB0212062D0 (en) Jetable compositions
IL165372A0 (en) Immunodenic compositions
GB0224415D0 (en) Compositions
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
GB0208609D0 (en) Compositions
GB0318894D0 (en) Composition
GB0203421D0 (en) Composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0221894D0 (en) Compositions
AU2003269904A8 (en) Antigen-polymer compositions
GB0203280D0 (en) Anti-glycolytic composition
GB0203395D0 (en) Compositions
GB0211924D0 (en) Composition
GB0203396D0 (en) Compositions
GB0229808D0 (en) Novel compositions
GB0318152D0 (en) Composition
GB0218241D0 (en) Composition
GB0217366D0 (en) Compositions
HK1082517A1 (en) Oil-barrier composition
EP1495751A4 (fr) Composition de colorant capillaire
GB2394114B (en) Compositions
AU2003216382A8 (en) Idothyronine compositions
GB0228540D0 (en) Novel compositions